MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
Brainstorm Cell Therapeutics ROA Ratio 2011-2026 | BCLI
Annual ROA Ratio Brainstorm Cell Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1008.51 | -634.44 | -408.56 | -287.27 | -83.54 | -62.06 | -355.88 | -124.23 | -43.35 | -46.28 | -49.7 | -93.29 | -103.66 | -64.6 | -142.78 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -43.35 | -1008.51 | -233.88 |
Quarterly ROA Ratio Brainstorm Cell Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -479.67 | -460.79 | -392.37 | -280.02 | -301.6 | -189.45 | -237.46 | -178.57 | -230.31 | -260.48 | -204.89 | -109.66 | -125.11 | -88.82 | -66.52 | -44.01 | -52.76 | -46.07 | -45.65 | -39.01 | -125.24 | -202.71 | -544.16 | -797.98 | -922.2 | -960.2 | -728.55 | -372.68 | -416.03 | -335.15 | -254.28 | -130.05 | -176.33 | -179.25 | -182.18 | -138.83 | -188.52 | -191.94 | -195.36 | -149.09 | -242.38 | -285.97 | -329.57 | -279.87 | -383.53 | -393.9 | -404.27 | -310.98 | -375.58 | -336.51 | -297.45 | -193.79 | -336.57 | -414.76 | -492.95 | -428.35 | -142.78 | -142.78 | -142.78 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -39.01 | -960.2 | -287.44 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M |  USA |
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Allakos
ALLK
|
-76.23 | - | - | $ 28.6 M | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 4.57 | -0.22 % | $ 11 B |  Australia |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | USA |
 |
Compugen Ltd.
CGEN
|
22.57 | $ 2.65 | -2.93 % | $ 248 M |  Israel |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-150.49 | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
-7.29 | $ 0.88 | - | $ 6.47 M | China |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
19.07 | $ 22.5 | -0.75 % | $ 3.73 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Applied Therapeutics
APLT
|
-218.41 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
Galapagos NV
GLPG
|
-1.99 | $ 27.55 | -3.08 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
22.5 | $ 25.89 | -3.36 % | $ 16 B |  Danmark |
 |
Avenue Therapeutics
ATXI
|
-99.25 | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | Israel |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-206.68 | - | 17.91 % | $ 11.1 M | USA |
 |
Atreca
BCEL
|
-62.67 | - | -11.76 % | $ 5.79 M | USA |
 |
BioNTech SE
BNTX
|
65.02 | $ 100.4 | -1.63 % | $ 27.2 B | Germany |
 |
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | USA |
 |
Innoviva
INVA
|
16.58 | $ 23.23 | -1.94 % | $ 1.57 B | USA |
 |
Innate Pharma S.A.
IPHA
|
-19.74 | $ 1.45 | 3.57 % | $ 235 M | France |
 |
Aquestive Therapeutics
AQST
|
-52.23 | $ 4.07 | -0.61 % | $ 435 M | USA |
 |
Inventiva S.A.
IVA
|
-40.69 | $ 4.96 | -1.1 % | $ 138 M | France |
 |
Jaguar Health
JAGX
|
-139.8 | $ 0.23 | -5.27 % | $ 536 K | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-3.73 | $ 22.56 | -3.13 % | $ 2.87 B | USA |
 |
KalVista Pharmaceuticals
KALV
|
-32.66 | $ 26.71 | 38.8 % | $ 1.44 B | Britain |
 |
Autolus Therapeutics plc
AUTL
|
-48.81 | $ 1.4 | -5.74 % | $ 373 M | Britain |
 |
Kamada Ltd.
KMDA
|
-0.7 | $ 8.15 | - | $ 260 M | Israel |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
0.11 | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
12.03 | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 2.88 | -1.03 % | $ 4.74 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
3.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |